Table 1.
STRIVE Hi dosing data and Ce end-points. Data presented as median [IQR (range)] or n (%). Cpt, predicted plasma-site concentration target; Ce, predicted effect-site concentration; Cptstart, starting Cpt; Cptincrements, incremental increase in Cpt during stepwise induction;. CeLOC, Ce at loss of consciousness; CeDL, Ce at direct laryngoscopy; CeSL, Ce at suspension laryngoscopy; CeMAX, maximum Ce attained; BPM, breaths per minute
| STRIVE Hi dose variables | |
|---|---|
| Cptstart (mcg.ml−1) | 2.0 (2.0–3.0 [2.0–3.0]) |
| Cptincrements (mcg.ml−1) | 1.0 (1.0–1.0 [0.5–1.0]) |
| CeLOC (mcg.ml−1) | 1.0 (0.7–1.5 [0.5–2.4]) |
| CeDL (mcg.ml−1) | 5.0 (5.0–5.5 [4.8–6.5]) |
| CeSL (mcg.ml−1) | 6.5 (6.2–6.8 [5.9–7.5]) |
| CeMax (mcg.ml−1) | 7.0 (7.0–7.0 [6.0–8.0]) |
| BPM at CeMax | 20 (18–22 [12–27]) |
| Vasopressor use during induction | 1 (3%) |
| Vasopressor use during maintenance | 4 (11%) |
| Remifentanil use during induction | 4 (13%) |
| Remifentanil use during maintenance | 21 (89%) |